|
|
Strategic Analysis of the Therapeutic Peptide Market in EuropePublished by: Frost & Sullivan Published: Oct. 20, 2004 Table of ContentsStrategic Analysis of the Therapeutic Peptides Market in Europe AbstractResearch OverviewThe Opportunity in Peptides Peptides have come a long way from the time of development to their use in therapeutics. The peptide therapeutics market is providing new commercial opportunities to biotechnology and pharmaceutical industries. To exploit these markets, biotechnology and pharmaceutical companies are actively pursuing the development of a variety of peptide-based technologies, peptide manufacturing technologies and drug delivery methods. What makes them blockbuster potential drugs is their specificity to the targets. The specificity of peptides has tremendous clinical value and makes them very attractive therapeutics. The focus, which was once dominated by their use in oncology, has now broadened to encompass additional disease areas. More than 40 peptides are in the world market out of which around four to five of them are marketed in Europe. Six are in the registration phase. About 270 peptides are in the clinical phase out of which for Europe, the number is 100. More than 400 are in advanced preclinical phases worldwide. For Europe, 150 are in advanced preclinical phases. The oncology segment accounts for the majority of therapeutic peptides market share contributing to around 60.0 per cent of total market. The entry of major pharmaceutical companies such as Roche and Merck have been encouraging. Technological Challenges There are many technological challenges associated with the therapeutic applications of peptide. Naturally occurring peptides often bind with more than one cellular receptor. While this natural peptide binding allows for regulation of multiple body functions, it can create risk with therapeutic use in terms of specificity. Peptides are generally unstable in the body and have short in vivo half life. This is particularly challenging when designing agents for oral administration, often the preferred administration route. It also requires large or frequent dosages, which challenges the large scale manufacturing of long peptides in a cost-effective manner. Problems with delivery technology is the requirement of high dosage amounts. This presents a challenge for cost-effective manufacturing of peptides in high amount. Purification adds significantly to the cost of the peptide. The success of new peptide products depends on the technology used to develop products and financial resources to test products in clinical trials. Companies cannot succeed in the peptide business without investing in technology to develop safe and effective products, and it certainly is a market that is long on potential. The pharmaceutical and biotechnology industry needs to continue to evolve towards technology integration and market expansions. Geographical Trends in Europe Germany, the United Kingdom, France, Italy, Scandinavia and Spain are the major therapeutic peptide markets in Europe. Germany is the largest market in Europe with 33.0 per cent market share and the United Kingdom comes second with 30.0 per cent of the total European market. Spain has the smallest share of 2.0 per cent due to fewer products in the market. Many products in Spain are in the clinical phase. Benefits of this Service Critical Analysis and Insight to the Therapeutic Peptides Market in Europe This research service critically analyzes the total European therapeutic peptides market including regional and segment wise analysis involving analysis of innovative and generic segments. Therapeutic segments have also been analysed. New Market Strategies The players need to analyse the dynamics of the market to optimize the opportunities present in the therapeutic peptides market. This market is in growing stage and thus to gain maximum competitive advantage, companies need an integrated approach for efficient therapeutic peptide manufacturing. The critical analysis and insight in this report will help the market players to adopt a strategy suitable for their business New Areas for Growth With the regional analysis provided in the report, the industry player would benefit with the key areas to enter. The market for United Kingdom, Germany, France, Scandinavia, Italy and Spain have been studied in this research service. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
The following technologies are covered in this research: Inhalable Drug Delivery: Inhalation or pulmonary delivery has emerged as the most promising field for both local delivery to the lungs and for the pulmonary delivery of systemic drugs. The pulmonary delivery of drugs for systemic effect offers a non-invasive alternative to injection that may achieve a more rapid onset and superior bioavailability than shown by other approaches such as oral, transdermal, or nasal delivery. The vast surface area of the lungs, which is approximately 1000 square feet, represents an attractive pathway for the non-invasive delivery of drugs. Injectable Drug Delivery: Despite advances in alternative drug delivery techniques, injectable delivery systems remain one of the most effective and reliable methods of delivering drugs in Europe. The application of injectable drug delivery has centred on the delivery of biotechnology drugs and anti-cancer agents. Transdermal Drug Delivery: One of the functions of the skin is to serve as a protective barrier and prevent the body from being damaged by outside agents. Transdermal drug delivery systems are the systems which can deliver medicines via the skin portal to the systemic circulation at a predetermined rate and maintain clinically effective concentrations over a prolonged period of time. This route of drug administration avoids the hazards and discomfort associated with parenteral therapy and improves patient compliance as it is easy to apply a patch. The bioavailability of a drug is increased when first-pass metabolism by the liver is avoided. Treatment can also be terminated rapidly by simply removing the patch when the need arises. Transdermal delivery may also eliminate the side effects that some drugs cause when presented in conventional forms. The delivery technique has evolved to iontophoresis, electropolation, or ultrasound assisted delivery. These techniques are being developed in order to deliver large molecules like proteins and peptides through the skin. Oral Delivery: Oral drug delivery technologies can be basically divided into immediate release and non-immediate release delivery systems. The immediate release formulations are also known as rapid release or fast dissolving. The other forms of oral delivery are taste-masking, and chewable tablets. Some of the companies are also developing delivery systems for proteins and peptides, which happens to be the most lucrative segment in drug delivery technologies. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||